SG11202010034WA - TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY - Google Patents

TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY

Info

Publication number
SG11202010034WA
SG11202010034WA SG11202010034WA SG11202010034WA SG11202010034WA SG 11202010034W A SG11202010034W A SG 11202010034WA SG 11202010034W A SG11202010034W A SG 11202010034WA SG 11202010034W A SG11202010034W A SG 11202010034WA SG 11202010034W A SG11202010034W A SG 11202010034WA
Authority
SG
Singapore
Prior art keywords
osmrß
disorders
antibody
delivery
treatment
Prior art date
Application number
SG11202010034WA
Inventor
John Paolini
Rohan Gandhi
Zamaneh Mikhak
Original Assignee
Kiniksa Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiniksa Pharmaceuticals Ltd filed Critical Kiniksa Pharmaceuticals Ltd
Publication of SG11202010034WA publication Critical patent/SG11202010034WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/522CH1 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
SG11202010034WA 2018-04-25 2019-04-25 TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY SG11202010034WA (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862662607P 2018-04-25 2018-04-25
US201862718324P 2018-08-13 2018-08-13
US201862765033P 2018-08-16 2018-08-16
US201862731618P 2018-09-14 2018-09-14
US201862757047P 2018-11-07 2018-11-07
US201862775350P 2018-12-04 2018-12-04
US201962789434P 2019-01-07 2019-01-07
US201962794356P 2019-01-18 2019-01-18
PCT/IB2019/000619 WO2019229525A2 (en) 2018-04-25 2019-04-25 TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY

Publications (1)

Publication Number Publication Date
SG11202010034WA true SG11202010034WA (en) 2020-11-27

Family

ID=68234020

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010034WA SG11202010034WA (en) 2018-04-25 2019-04-25 TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY

Country Status (11)

Country Link
US (2) US20210054085A1 (en)
EP (1) EP3784347A2 (en)
JP (1) JP2021522241A (en)
KR (1) KR20210018808A (en)
CN (1) CN112533675A (en)
AU (1) AU2019276779A1 (en)
BR (1) BR112020021739A2 (en)
CA (1) CA3096582A1 (en)
MX (1) MX2020011172A (en)
SG (1) SG11202010034WA (en)
WO (1) WO2019229525A2 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012202218B2 (en) * 2005-02-14 2014-05-22 National Jewish Medical And Research Center Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
WO2006088956A2 (en) * 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists
US9475876B2 (en) * 2012-05-11 2016-10-25 Wakayama Medical University Anti oncostatin M receptor beta antibody used for treating atopic dermatitis
MX351127B (en) * 2013-05-30 2017-10-03 Kiniksa Pharmaceuticals Ltd Oncostatin m receptor antigen binding proteins.
TWI755763B (en) * 2013-06-04 2022-02-21 美商再生元醫藥公司 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
AU2016210996B2 (en) * 2015-01-29 2021-08-12 Oxford University Innovation Limited Therapeutic target and biomarker in IBD
KR102514173B1 (en) * 2015-04-14 2023-03-27 추가이 세이야쿠 가부시키가이샤 Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient

Also Published As

Publication number Publication date
EP3784347A2 (en) 2021-03-03
AU2019276779A1 (en) 2020-12-10
JP2021522241A (en) 2021-08-30
WO2019229525A3 (en) 2020-03-19
US20210054085A1 (en) 2021-02-25
MX2020011172A (en) 2021-01-29
US20240101690A1 (en) 2024-03-28
CA3096582A1 (en) 2019-12-05
CN112533675A (en) 2021-03-19
BR112020021739A2 (en) 2021-01-26
WO2019229525A2 (en) 2019-12-05
KR20210018808A (en) 2021-02-18

Similar Documents

Publication Publication Date Title
PT3377637T (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
IL276383A (en) Treatment of ophthalmologic diseases
EP3429605A4 (en) Therapeutic for treatment of diseases including the central nervous system
EP4009948A4 (en) Use of tgf-alpha polypeptide or anti-tgf-alpha antibodies for the treatment of diseases and disorders
SG11202006374VA (en) Treatment of demyelinating diseases
IL278041A (en) Buffered formulations of bevacizumab for use of treating diseases
ZA201906213B (en) Compounds and methods for the treatment of parasitic diseases
IL289405A (en) Personalized treatment of ophthalmologic diseases
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
SG11202010585WA (en) New treatment of interstitial lung diseases
IL282643A (en) Combination therapy for treatment of hematological diseases
EP3897641C0 (en) Treatment of movement disorders
GB201620611D0 (en) Treatment of neurological diseases
ZA202002075B (en) Compounds, compositions and methods for treatment of eye disorders and skin diseases
SG11202001595SA (en) Angio-3 for treatment of retinal angiogenic diseases
SG11202007082PA (en) Composition used for therapeutic treatment of skin disease
GB201805100D0 (en) Treatment of sarcopenic diseases
IL282361A (en) Treatment of neurological diseases
SG11202010034WA (en) TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY
GB201909438D0 (en) Treatment of diseases
EP4028057A4 (en) Treatment of skin blistering diseases using antibodies
IL274132A (en) Treatment of skin disorders
GB201811912D0 (en) Treatment of disease
GB201811911D0 (en) Treatment of disease
GB201810974D0 (en) Treatment of disease